Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Biosante Pharma Charts. Click Here for more Biosante Pharma Charts.](/p.php?pid=staticchart&s=A%5EBPA&p=8&t=15)
BioSante Pharmaceuticals (AMEX:BPA) today announced that
Stephen M. Simes, president and chief executive officer, will present
a corporate overview at the Rodman & Renshaw Techvest 2nd Annual
Global Healthcare Conference. The presentation will take place on May
5, 2005 at 7:00 a.m. EDT (1:00 p.m. local Paris time) at the
Intercontinental Hotel in Paris, France.
The Rodman & Renshaw Techvest 2nd Annual Global Healthcare
Conference is expected to include more than 160 presenting companies
and more than 700 attendees. A live audio webcast of the presentation
can be accessed on the internet by visiting
http://www.wsw.com/webcast/rrshq5/bpa/. Beginning May 5, a replay of
the presentation will be available at the same link for 90 days. For
more information on the Rodman & Renshaw Conference, visit
www.rodmanandrenshaw.com/eu05conference.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to
treat both men and women. These hormone therapy products are gel
formulations for transdermal administration that deliver bioidentical
estradiol and testosterone. BioSante's lead products include
Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women
with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone
gel) for the treatment of female sexual dysfunction (FSD). The current
market in the U.S. for estrogen and testosterone products is
approximately $2.5 billion. The company also is developing its calcium
phosphate nanotechnology (CAP) for novel vaccines, including
biodefense vaccines for toxins such as anthrax and ricin, and drug
delivery systems. Additional information is available online at
www.biosantepharma.com.
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. The
statements regarding BioSante contained in this press release that are
not historical in nature, particularly those that utilize terminology
such as "may," "will," "should," "likely," "expects," "anticipates,"
"estimates," "believes" or "plans," or comparable terminology, are
forward-looking statements. Forward-looking statements are based on
current expectations and assumptions, and entail various risks and
uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements. Important
factors known to BioSante that cause actual results to differ
materially from those expressed in such forward-looking statements are
the difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance, and
other factors identified and discussed from time to time in BioSante's
filings with the Securities and Exchange Commission, including those
factors discussed on pages 19 to 31 of BioSante's Form 10-KSB, which
discussion also is incorporated herein by reference.